spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

3D Cell Culture 2018

SMi - 3D Cell Culture 2018

21-22 February 2018
Holiday Inn Kensington Forum, London UK

Building on the sell-out success of the launch event, SMi Group is delighted to announce the return of 3D Cell Culture, taking place on 21st and 22nd of February 2018, in London UK.

3D Cell Culture is rapidly growing with incredible potential for industrial application and a widespread reach that can be seen across many different fields, such as 3D bioprinting and microfluidics.

The 2nd annual conference will explore these overlapping areas and will combine pioneering breakthroughs with scientific research to strengthen your commercial success. Join us for exclusive insight into key topics such as disease models, organoids, organ-on-a-chip technologies, iPSC advances plus much more!

FEATURED SPEAKERS:

·        Gary Allenby, Business Development Director and Chief Scientific Officer, Aurelia Bioscience

·        Mr Stefan Przyborski, Scientific Founder, ReInnervate Limited

·        Mr Ricardo Baptista, Lead Scientist Process Development, Cell and Gene Therapy Catapult

·        Dr Nicholas Leslie, Tumour Biologist, Heriot-Watt University

·        Dr Suwan Jaysinghe, Professor of Bioengineering, University College London

·        Dr Max Salick, Postdoctoral Researcher, Novartis Institutes for Biomedical Research

·        Dr Patrick Kugelmeier, Director of Science, Kugelmeiers

·        Dr Vitor Santo, Senior Scientist, Immunocore

·        Mr Christopher Schofield, Investigator, GSK

·        Mr David Pan, Programme Manager (Regenerative Medicine), UK Regenerative Medicine Platform

·        Dr Reyk Horland,Head of Business Development, TissUse GmbH


REASONS TO ATTEND IN 2018

·        Uncover the biology of human neurodevelopment diseases in 3D by merging cutting edge technologies in CRISPR editing and single cell sequencing

·        Take a 3D biology approach to overcome challenges for well based screening with exclusive insight into electrospun micro-scaffold based biology

·        Develop strategies for optimising placement of cells in printing by identifying key developments in the overlap of 3D bioprinting and 3D cell culturing

·        Discover new approaches to predictive substance testing through innovative case study insight into multi-organ-chip technology

·        Benefit from an agenda tailored towards driving clinical development through ground breaking case studies on the Zika virus and tuberous sclerosis


2017 ATTENDEE TESTIMONIALS

“Very good presentations and a few outstanding ones... I made some useful contacts” ASTERAND BIOSCIENCE

“The conference was wonderfully organised” NOVARTIS

“Good start, love to see the event occur again” THERMO FISHER SCIENTIFIC

For further details visit www.3D-cellculture.com/samedan or contact the team on +44 (0)20 7827 6000

 

phone +44 (0)20 7827 6000
email events@smi-online.co.uk
web www.3D-cellculture.com/samedan
email Holiday Inn Kensington Forum, London UK
 
Print this page
Send to a friend
   
spacer
Industry Events

SMi’s 9th Annual Biosimilars & Biobetters Conference

25-27 September 2018, Copthorne Tara Hotel, London, UK

Following the success of our previous events in both London and the US, Biosimilars and Biobetters UK 2018, SMi deliver a stellar speaker line-up and bring together a global audience of biosimilar experts to discuss the latest developments and future of the rapidly evolving and expanding biosimilars market.
More info >>

Banner of PHPL West Coast_events_95 on Samedan Banner of Nordics_Events_97 on Samedan

White Papers

Clinical Trials in Russia Orange Paper: 2nd Quarter 2014

Synergy Research Group

The Ministry of Health of Russian Federation approved 194 new clinical trials of all types including local and bioequivalence studies during the 2nd Quarter of 2014 (3% less than at the same period of the last year). The main contribution to the total number of studies was made by multinational multi-center clinical trials (MMCT) and the number of these studies stayed the same as in Q2 2013 – 81 studies. The number of bioequivalence studies (BE) decreased from 76 studies in Q2 2013 to 59 in Q2 2014, a 22% decrease from last year’s figure. The number of local clinical trials (LCT) increased from 42 in Q2 2013 to 54 clinical trials in Q2 2014.
More info >>


News and Press Releases

BioIVT Acquires Optivia Biotechnology, Adding Transporter Assay Products and Services to its ADME-Tox Portfolio

BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Santa Clara, CA-based Optivia Biotechnology and its comprehensive portfolio of transporter assays, multi-transporter models, transporter systems biology, and molecular transport research solutions.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement